Research Compensation and Reimbursement payments are more than an operational detail. A well-designed approach can reduce barriers to participation, support retention, and protect voluntariness—while making it easier for study teams to administer payments consistently and document them accurately.
The information below is a practicle overview and guide of research compensation and reimbursement for human subjects research, including ethical considerations, practical payment models, and best practices commonly expected by IRBs and research organizations. Payment design is highly context-specific; study teams should align with their institution’s policies and consult their IRB and finance/tax partners.
Separate reimbursement from compensation. Reimbursement covers participant out-of-pocket expenses (e.g., travel, parking, meals, childcare). Compensation pays for time and inconvenience. Keeping these distinct improves fairness, budgeting, and IRB review clarity.
Design payments to protect voluntariness. Payment should not pressure participation or continued enrollment. Avoid “all-or-nothing” structures and ensure the consent process clearly explains payment terms.
Prorate payments for partial participation. A common best practice is to pay per visit/procedure completed and to compensate participants for what they complete even if they withdraw.
Reduce barriers to participation and retention. Transportation and logistical costs can be real obstacles; covering reasonable expenses and paying promptly can support recruitment and retention—especially for participants with fewer resources.
Offer accessible payment options where feasible. Participants vary in banking access and preferences. Methods that are fast, usable, and transparent (including fee transparency) improve the participant experience and reduce support burden.
Plan for privacy and data minimization. Payment administration often requires identifying information; limit access by role, collect only what’s necessary, and separate research data from payment records when possible.
Treat documentation as part of the protocol. Define a standard schedule, approvals, exception handling (voids/reissues), and reconciliation so payments are consistent and auditable across studies.
Coordinate early with finance/tax stakeholders. Organizations often have thresholds and processes for tax reporting (e.g., 1099-related workflows). Align the payment plan with institutional policy before launch to avoid mid-study rework.
Different guidance sources use slightly different terminology, but most converge on a few practical categories:
Reimbursement covers out-of-pocket costs a participant incurs because of the study (for example: transportation, parking, meals, lodging, or childcare). The FDA notes that reimbursement for travel and associated costs generally does not raise the same undue influence concerns as payment for participation, and IRBs should still ensure the plan is reasonable and appropriate. U.S. Food and Drug Administration
The MRCT Center (Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard) describes reimbursement as restoring participants to their financial baseline and recommends itemizing costs so they are not overlooked. Brigham Clinical Trials Center
Compensation typically refers to payment for a participant’s time, inconvenience, and burden. CIOMS (International Ethical Guidelines for Health-related Research Involving Humans) states participants should be reasonably compensated for time and inconvenience, and that compensation should not be so large that it induces participation against a person’s better judgment. NCBI
NIH policy similarly emphasizes that compensation should be based on time and inconvenience and should be structured to avoid undue influence, including by paying participants who withdraw for the portions they completed. policymanual.nih.gov
Incentives go beyond making participants whole (reimbursement) or paying for time/inconvenience (compensation). They are intended to make participation more attractive and may increase the risk of undue influence in some contexts. The University of Washington’s IRB guidance summarizes this clearly: reimbursement and compensation are generally less likely to unduly influence participants than incentives. UW Homepage
eimbursement covers out-of-pocket costs a participant incurs because of the study (for example: transportation, parking, meals, lodging, or childcare). The FDA notes that reimbursement for travel and associated costs generally does not raise the same undue influence concerns as payment for participation, and IRBs should still ensure the plan is reasonable and appropriate. U.S. Food and Drug Administration
The MRCT Center (Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard) describes reimbursement as restoring participants to their financial baseline and recommends itemizing costs so they are not overlooked. Brigham Clinical Trials Center
Ethical and regulatory foundations (why this matters) – Payment design intersects with core human subjects protections:
The Belmont Report explains that informed consent must be voluntary and free from coercion and undue influence, defining undue influence as an “excessive, unwarranted, inappropriate or improper reward” offered to obtain compliance. HHS
FDA guidance states that payment for participation is not considered a benefit in the risk/benefit calculus; it is a recruitment incentive. U.S. Food and Drug Administration
This matters because it helps keep the consent conversation focused on the actual study purpose, procedures, risks, and alternatives.
While regulations don’t prescribe a single “correct” amount, major guidance commonly expects:
A clear justification for payment amounts and structure
Transparent description of payment terms in the consent materials
Safeguards so payment does not pressure someone to stay in a study when they want to withdraw. NIH policy explicitly recommends prorating payments for completed visits rather than making payment contingent on full study completion. policymanual.nih.gov
FDA likewise emphasizes IRB sensitivity to undue influence and the importance of fairness. U.S. Food and Drug Administration
A practical way to design participant payments is to separate the work into three steps:
Create a simple inventory:
Direct expenses: travel, parking, transit fares, tolls, lodging, meals, childcare
Time burden: visit duration, commute time, waiting time, remote check-ins
Inconvenience/burden: fasting, diaries, multiple blood draws, time off work, disruption to caregiving responsibilities
Population considerations: minors, older adults, rural participants, people with limited transportation access, people without bank accounts
Transportation costs in particular are widely recognized as a barrier to research participation and can contribute to disparities. PubMed Central
Reimbursement: cover reasonable expenses so participants are not paying to contribute to research (a fairness theme across guidance). NCBI
Compensation: pay for time/inconvenience in a way that is consistent and explainable. policymanual.nih.gov
Incentives (optional): use carefully, justify clearly, and avoid structures that could pressure continued participation. HHS
A “good” structure is one that your team can:
Explain plainly to participants
Implement reliably at scale
Prorate fairly
Document for auditing/reconciliation
Reimbursement should do one thing well: cover participation-related costs clearly and consistently—so money doesn’t become a barrier to enrollment or retention.
MRCT recommends itemizing reimbursement “with as much detail as possible” and frames it as restoring participants to baseline. Brigham Clinical Trials Center
This helps research teams avoid unintentionally excluding participants for whom parking, transit, or childcare is a real barrier.
Long delays can turn reimbursement into a financial burden—especially for participants living paycheck-to-paycheck. Consider:
Same-day reimbursement when feasible
Clear timelines (“within X days of visit completion”)
Simple receipt rules (and alternatives when receipts are impractical)
Some organizations treat reimbursement as covering costs whether paid upfront by the participant or supported directly by the study (for example: providing transit vouchers, rideshare support, or pre-paid parking). The key is that it’s tied to participation-related costs and is reasonable.
Travel and time burdens are consistently cited barriers to participation. A 2025 review highlights transportation as a common barrier and notes many institutions lack clear guidance, which can make it harder for study teams to address transportation needs effectively. PubMed Central
Participant compensation works best when it’s fair, transparent, and tied to effort—so it recognizes time without creating pressure to stay enrolled.
Both NIH policy and international ethics guidance emphasize compensation for time and inconvenience and caution against undue inducement. policymanual.nih.gov
Proration is one of the most consistent best practices across IRB-facing guidance:
NIH: payment “should ideally be prorated for completed visits,” and participants who withdraw should receive compensation for what they completed. policymanual.nih.gov
OHRP-related ethics analyses likewise emphasize describing conditions for partial payment in consent materials. PubMed Central
Making payment contingent on completing every activity can pressure people to remain enrolled when they would otherwise withdraw. A safer pattern is:
Pay per visit/procedure completed
Pay milestones that reflect completed effort
Keep any completion component modest and clearly justified (if used at all)
FDA recommends that IRBs address “how much” and “for what” participants are paid and underscores the importance of fairness and voluntariness. U.S. Food and Drug Administration
NIH requires IRB review of compensation plans and how they are described in consent forms. policymanual.nih.gov
Not all study payments serve the same purpose—“thank you” tokens, incentives, and completion bonuses each carry different ethical considerations and should be designed accordingly.
SACHRP notes small “thank you” payments are not intended to meaningfully reimburse or compensate and are unlikely to raise undue influence concerns due to their minimal nature. HHS
SACHRP distinguishes incentives from reimbursement/compensation and notes incentives can create undue influence concerns in some cases, but those concerns can often be managed with appropriate safeguards rather than banning incentives outright. HHS
Keep the incentive proportionate and explain the rationale
Avoid structures that discourage withdrawal (for example, large end-loaded payments)
Ensure the consent process is robust and not dominated by payment messaging
Consider participant vulnerability and local context (Belmont’s caution that acceptable inducements can become undue influences for vulnerable populations is relevant here). HHS
Participant compensation works best when it’s fair, transparent, and tied to effort—so it recognizes time without creating pressure to stay enrolled.
Both NIH policy and international ethics guidance emphasize compensation for time and inconvenience and caution against undue inducement. policymanual.nih.gov
Cash (simple, but policy and security concerns)
Checks (trackable, but slow and can be burdensome to cash)
Gift cards (good for some contexts; may not meet participant needs; may have restrictions)
Prepaid debit cards (fast, broadly usable; watch fee transparency)
ACH/direct deposit (efficient; requires bank account)
Digital wallets (fast; requires access and comfort with the tool)
Making payment contingent on completing every activity can pressure people to remain enrolled when they would otherwise withdraw. A safer pattern is:
Pay per visit/procedure completed
Pay milestones that reflect completed effort
Keep any completion component modest and clearly justified (if used at all)
Some universities explicitly describe using dedicated participant payment systems to improve tracking, speed, and security (for example, Brown notes use of a participant payment system and requires consent language/FAQs for that system). Division of Research
Payment workflows can introduce privacy risks because they may require identifying information (and, in some institutions, tax information). Northeastern’s guidance notes that compensation should be equitable and that measures should be in place to protect the confidentiality of payment-related information. Human Subject Research Protection
Collect only what you need, when you need it
Restrict access by role (e.g., study team vs finance)
Separate research data from payment administration data where possible
Use secure storage and transmission (especially for tax identifiers)
Define retention schedules and deletion processes aligned with institutional policy
Because participant payments can trigger tax reporting obligations, study teams should plan early for documentation, thresholds, and participant communications.
Tax treatment and reporting can vary by institution and payment type, but some common patterns appear in university guidance:
Institutions often issue Form 1099-MISC when payments to an individual meet certain thresholds in a calendar year (commonly referenced at $600). UVA Finance+2Division of Research+2
The IRS “About Form 1099-MISC” page describes reporting categories with a $600 threshold for certain payments (context-specific). IRS
University guidance often notes the operational consequence: collecting name/address and (when required) taxpayer identification information, and protecting that information carefully. UVA Finance+1
Important: This is an overview, not tax advice. Study teams should follow institutional policy and consult finance/tax leadership for how reimbursement vs compensation is treated locally, what documentation is required, and what participant-facing disclosures should be included.
The best payment operations are boring in the best way—repeatable, auditable, and easy for participants to understand.
Confirm sponsor/funder allowability and constraints
Align the payment plan with IRB expectations and institutional finance policy
Ensure consent language matches the operational plan (timing, proration, withdrawal)
Build the budget to reflect reality:
Total expected reimbursement costs (including “edge cases” like rural travel)
Payment method costs (processing, replacement, support)
Staffing time for reconciliation and exceptions
A common, defensible approach:
Reimbursement: per visit (or per documented expense), paid promptly
Compensation: per completed visit/procedure or hourly equivalent
Incentives: if used, keep modest and avoid end-loaded pressure
NIH’s policy explicitly supports paying participants who withdraw for activities completed. policymanual.nih.gov
Participants should be able to answer:
How much will I receive, and when?
What if I withdraw?
What if the study ends early or I’m removed for safety reasons?
Are there any tax implications I should know about?
FDA recommends payment details be addressed thoughtfully by IRBs and underscores fairness. U.S. Food and Drug Administration
Maintain a consistent record of:
Payment authorizations (who approved, when, under what rules)
Payment delivery (date, method, amount)
Exception handling (returned payments, reissues, cancellations)
Participant-facing issues and resolution
A participant-centric experience reduces drop-off. A clinical trial retention review notes that travel reimbursement and meal vouchers can help retention, and that incentives should be planned with ethics committee approval to avoid coercion/undue influence. PubMed Central
These examples are meant to be adapted to your institution’s templates and IRB requirements.
Payment and expenses:
You will be reimbursed for reasonable study-related expenses (for example, parking or public transportation) for each completed visit. You will also receive $X for each completed study visit to compensate you for your time and effort. If you choose to stop participating, you will still receive payment for the visits you completed.
Thank you payment:
To thank you for your time, you will receive a one-time $X payment after you complete the survey. You may skip any question you do not want to answer.
Payment schedule:
You will receive $X after each completed visit. If you complete all scheduled visits, you will receive an additional $Y at the final visit. If you stop participating early, you will still receive payment for each visit you completed.
(Completion components are where IRBs often look closely; if used, keep the rationale clear and avoid making the completion amount so large that it pressures continued participation.)
These FAQs address common questions IRBs and study teams raise about participant payment, using plain language grounded in widely cited guidance.
FDA guidance says payment is generally considered a recruitment incentive, not a benefit in the risk/benefit assessment. U.S. Food and Drug Administration
Reimbursement covers expenses incurred because of participation; compensation covers time and inconvenience. Many IRB and ethics sources treat reimbursement as less likely to create undue influence when it is reasonably estimated. UW Homepage, Brigham Clinical Trials Center
Many policies recommend proration. NIH policy states participants who withdraw should receive compensation for study activities completed. policymanual.nih.gov
Not necessarily. SACHRP notes incentive payments can raise undue influence concerns in some cases, but concerns can often be managed with safeguards rather than eliminating incentives entirely. HHS
There’s no single numeric threshold across all studies. Belmont defines undue influence conceptually and notes it is context-dependent and can be heightened by vulnerability. HHS
A practical approach is to justify the plan based on time/burden and baseline expenses, ensure proration, and use a robust consent process.
FDA: Payment and Reimbursement to Research Subjects U.S. Food and Drug Administration
NIH Policy Manual 3014-302: Subject Recruitment and Compensation policymanual.nih.gov
Belmont Report (HHS/OHRP) HHS
SACHRP recommendations on payment categories and undue influence HHS
MRCT Center (2022): Payments to Participants (IRB resource) Brigham Clinical Trials Center
CIOMS Guideline 13: Reimbursement and compensation NCBI
University of Washington IRB guidance: Subject Payment UW Homepage
Transportation barriers and policy gaps (2025 review) PubMed Central
Retention strategies review noting reimbursement support PubMed Central
IRS: About Form 1099-MISC IRS and institutional tax guidance examples UVA Finance
A short demo is the perfect way to show you how TruCentive can help you realize your rewards, gifts, or payout goals in a real-world scenario, building a complete project with everything from your logo, design options, and messaging to incentive selection, deliveries, and reminders.
When we’re done, you’ll:
If you’re ready to start designing on your own, sign up and start sending samples. There’s no credit card required to start exploring your creative side!
Use powerful features to quickly create professional-looking incentive deliveries
With a TruCentive subscription, you get technical support for all your team members so you can get back to your project fast
Eliminate the time and frustration managing the procurement, delivery, and management of your rewards and incentives deliveries
